Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2 positive colorectal, endometrial, gastroesophageal, and metastatic breast cancer.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Pipeline

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

Program
(Target)
IndicationDiscoveryPreclinicalPhase 1Phase 2
Proprietary Development Programs
BDC-1001
HER2

HER2+ Colorectal, Endometrial, Gastroesophageal Cancer

HER2+ Metastatic Breast Cancer*

Phase 2

Monotherapy & nivolumab combination studyMono and nivolumab combination

Phase 2

Monotherapy & pertuzumab§ combination studyMono and pertuzumab combination§
BDC-3042
Dectin-2

Range of Solid Tumors

Preclinical

IND-enabling activities
Next-Gen ISAC
Undisclosed

Range of Solid Tumors

Discovery

Discovery
Next-generation Boltbody™ ISAC Collaborations

Genmab

Bispecific Boltbody ISACs
Undisclosed

Discovery

Innovent

Boltbody ISACs
Undisclosed

Discovery

Toray

Boltbody ISAC
Undisclosed

Discovery

* Previously treated with Enhertu
Collaboration using Bristol-Myers Squibb’s PD-1 inhibitor nivolumab
§ Collaboration using Roche’s HER2 antagonist pertuzumab

*Dectin-2, also known as TAM1

© 2023 - Bolt Biotherapeutics - All rights reserved.